登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT04944914,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Imageological evidence for oligometastatic lesions (metastatic tissue biopsy preferred but not necessary). The number of total metastatic lesions no more than 5 and the number of metastatic lesions within a single organ no more than 3.
入选标准第 4 条
ECOG performance status of 0 or 1.
入选标准第 5 条
Active tuberculosis (TB), anti-TB treatment is ongoing or within 1 year prior to screening
排除标准第 11 条
Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive.
排除标准第 13 条
Pregnancy or lactation.
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT04944914,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female; 18-70 years of age. Primary lesion and regional lymph nodes completed radical radiotherapy 3 months before stereotactic body radiotherapy and diseases well controlled. Underwent at least first-line systemic chemotherapy, regardless of regimen and curative effect. Imageological evidence for oligometastatic lesions (metastatic tissue biopsy preferred but not necessary). The number of total metastatic lesions no more than 5 and the number of metastatic lesions within a single organ no more than 3. ECOG performance status of 0 or 1. Stereotactic body radiotherapy applicable for all metastatic lesions according to MDT. If metastatic lesions have received local treatment (surgery, radiofrequency ablation, radiotherapy etc.): Eligible if treated lesion is well controlled according to imageological examinations, and the lesion does not need stereotactic body radiotherapy. If treated lesion is not controlled according to imageological examinations: Eligible if the treatment is surgery and that stereotactic body radiotherapy is applicable for the treated lesion. Ineligible if the treatment is radiofrequency ablation or radiotherapy. Maximum diameter of brain metastatic lesion no more than 3cm. Maximum diameter of metastatic lesion (brain excluded) no more than 5cm. Maximum diameter of bone metastatic lesion no more than 6cm if attending doctor decides it is safe to apply the treatment. Life expectancy more than 12 weeks.排除标准:Exclusion Criteria:
Immunotherapy (PD-1/PD-L1 or CTLA-4 monoclonal antibody) failure. CHD no less than grade 2, arrhythmia (QTc interval over 450ms for male and 470ms for female) or cardiac insufficiency. History of severe hypersensitivity to any ingredient of PD-1/PD-L1 or other monoclonal antibody. chemotherapy (cytotoxic or molecular targeted) within 4 weeks before stereotactic body radiotherapy. Imageological evidence for spinal cord compression, or tumor less than 3mm away from spinal cord. Patient with brain metastasis who needs decompression surgery. Other malignancy or malignant hydrothorax. Concurrent known or suspicious autoimmune disease, including dementia and epilepsy. Use of large dose corticosteroids within 4 weeks before study drug administration. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Active tuberculosis (TB), anti-TB treatment is ongoing or within 1 year prior to screening Subjects with any active autoimmune disease or history of autoimmune disease, or history of syndrome that requires systemic steroids or immunosuppressive medications, including but not limited to the following: rheumatoid arthritis, pneumonitis, colitis (inflammatory bowel disease), hepatitis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Has a known history of human immunodeficiency virus (HIV), has hepatitis B surface antigen (HBsAg) positive with hepatitis B virus (HBV) DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive. Received any anti-infective vaccine (e.g. influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment. Pregnancy or lactation. Other ineligible patients according to attending doctor.
引自 ClinicalTrials.gov, NCT04944914, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT04944914,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。